Johanna Bendell

Johanna Bendell at Sarah Cannon Research Institute is a prolific clinical trial leader in gastrointestinal oncology who has contributed to multiple pivotal CRC studies. Her involvement in early-phase trials of fruquintinib and other VEGFR inhibitors helped establish their activity in refractory CRC. She has led first-in-human trials of numerous novel agents in CRC and other GI malignancies. Her work on the FRESCO-2 international trial helped establish fruquintinib as an approved option for refractory metastatic CRC.